QQQ   438.20 (-1.61%)
AAPL   175.81 (+0.44%)
MSFT   421.30 (-1.55%)
META   513.21 (-1.90%)
GOOGL   157.58 (-1.15%)
AMZN   185.78 (-1.73%)
TSLA   171.40 (-1.83%)
NVDA   886.38 (-2.18%)
AMD   163.37 (-4.18%)
NIO   4.13 (-7.40%)
BABA   71.88 (-3.97%)
T   16.33 (-0.55%)
F   12.57 (-3.60%)
MU   122.78 (-3.71%)
GE   154.76 (-1.68%)
CGC   7.87 (-3.44%)
DIS   114.32 (-2.42%)
AMC   2.67 (-4.64%)
PFE   25.96 (-1.44%)
PYPL   64.38 (-2.16%)
XOM   120.98 (-0.67%)
QQQ   438.20 (-1.61%)
AAPL   175.81 (+0.44%)
MSFT   421.30 (-1.55%)
META   513.21 (-1.90%)
GOOGL   157.58 (-1.15%)
AMZN   185.78 (-1.73%)
TSLA   171.40 (-1.83%)
NVDA   886.38 (-2.18%)
AMD   163.37 (-4.18%)
NIO   4.13 (-7.40%)
BABA   71.88 (-3.97%)
T   16.33 (-0.55%)
F   12.57 (-3.60%)
MU   122.78 (-3.71%)
GE   154.76 (-1.68%)
CGC   7.87 (-3.44%)
DIS   114.32 (-2.42%)
AMC   2.67 (-4.64%)
PFE   25.96 (-1.44%)
PYPL   64.38 (-2.16%)
XOM   120.98 (-0.67%)
QQQ   438.20 (-1.61%)
AAPL   175.81 (+0.44%)
MSFT   421.30 (-1.55%)
META   513.21 (-1.90%)
GOOGL   157.58 (-1.15%)
AMZN   185.78 (-1.73%)
TSLA   171.40 (-1.83%)
NVDA   886.38 (-2.18%)
AMD   163.37 (-4.18%)
NIO   4.13 (-7.40%)
BABA   71.88 (-3.97%)
T   16.33 (-0.55%)
F   12.57 (-3.60%)
MU   122.78 (-3.71%)
GE   154.76 (-1.68%)
CGC   7.87 (-3.44%)
DIS   114.32 (-2.42%)
AMC   2.67 (-4.64%)
PFE   25.96 (-1.44%)
PYPL   64.38 (-2.16%)
XOM   120.98 (-0.67%)
QQQ   438.20 (-1.61%)
AAPL   175.81 (+0.44%)
MSFT   421.30 (-1.55%)
META   513.21 (-1.90%)
GOOGL   157.58 (-1.15%)
AMZN   185.78 (-1.73%)
TSLA   171.40 (-1.83%)
NVDA   886.38 (-2.18%)
AMD   163.37 (-4.18%)
NIO   4.13 (-7.40%)
BABA   71.88 (-3.97%)
T   16.33 (-0.55%)
F   12.57 (-3.60%)
MU   122.78 (-3.71%)
GE   154.76 (-1.68%)
CGC   7.87 (-3.44%)
DIS   114.32 (-2.42%)
AMC   2.67 (-4.64%)
PFE   25.96 (-1.44%)
PYPL   64.38 (-2.16%)
XOM   120.98 (-0.67%)
OTCMKTS:XSNX

NovAccess Global (XSNX) Stock Price, News & Analysis

$0.01
0.00 (0.00%)
(As of 04/11/2024 ET)
Today's Range
$0.01
$0.0110
50-Day Range
$0.01
$0.03
52-Week Range
$0.01
$0.22
Volume
700,120 shs
Average Volume
508,513 shs
Market Capitalization
$349,800.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
XSNX stock logo

About NovAccess Global Stock (OTCMKTS:XSNX)

NovAccess Global Inc., a biopharmaceutical company, develops novel immunotherapies to treat brain tumor patients in the United States. It specializes in cutting-edge research related to utilizing a patient's immune system to attack the cancer. The company was incorporated in 1997 and is headquartered in Chagrin Falls, Ohio.

XSNX Stock Price History

XSNX Stock News Headlines

The next Nvidia (and it’s not Microsoft or Facebook)
Imagine buying Bitcoin at $1,000. That would have been the trade of the decade... right? Well, I think there's an even bigger play to be made in the A.I. space.
NovAccess Global Announces $10.7 Million Financing
The next Nvidia (and it’s not Microsoft or Facebook)
Imagine buying Bitcoin at $1,000. That would have been the trade of the decade... right? Well, I think there's an even bigger play to be made in the A.I. space.
Novaccess Global Inc XSNX
XSNX - NovAccess Global Inc.
NovAccess Global to Present at World Orphan Drug Congress
See More Headlines
Receive XSNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NovAccess Global and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
4/12/2024
Fiscal Year End
9/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:XSNX
Employees
3
Year Founded
N/A

Profitability

Net Income
$-4,720,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.58) per share

Miscellaneous

Free Float
31,345,000
Market Cap
$349,800.00
Optionable
Not Optionable
Beta
1.51
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Dwain K. Morris-Irvin M.P.H. (Age 56)
    MPH, Ph.D., CEO & Director
    Comp: $155.43k
  • Mr. Neil J. Laird (Age 71)
    Chief Financial Officer
  • Dr. Christopher Wheeler Ph.D.
    President of Stemvax Therapeutics

XSNX Stock Analysis - Frequently Asked Questions

How have XSNX shares performed in 2024?

NovAccess Global's stock was trading at $0.0201 at the start of the year. Since then, XSNX shares have decreased by 45.3% and is now trading at $0.0110.
View the best growth stocks for 2024 here
.

Are investors shorting NovAccess Global?

NovAccess Global saw a increase in short interest in March. As of March 31st, there was short interest totaling 65,900 shares, an increase of 16,375.0% from the March 15th total of 400 shares. Based on an average trading volume of 621,800 shares, the days-to-cover ratio is presently 0.1 days.
View NovAccess Global's Short Interest
.

How were NovAccess Global's earnings last quarter?

NovAccess Global Inc. (OTCMKTS:XSNX) announced its earnings results on Tuesday, February, 27th. The company reported $0.01 EPS for the quarter.

What other stocks do shareholders of NovAccess Global own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NovAccess Global investors own include Co-Diagnostics (CODX), iBio (IBIO), SANUWAVE Health (SNWV), Sierra Oncology (SRRA), Tonix Pharmaceuticals (TNXP), T2 Biosystems (TTOO), Kopin (KOPN), Ascent Solar Technologies (ASTI) and BioRestorative Therapies (BRTX).

How do I buy shares of NovAccess Global?

Shares of XSNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:XSNX) was last updated on 4/12/2024 by MarketBeat.com Staff

From Our Partners